Innate Pharma (IPHA) Change in Intangibles (2019 - 2023)

Innate Pharma has reported Change in Intangibles for 5 years, with the latest figure at -$2.2 million in Q4 2023.

• For the quarter ending Q4 2023, Change in Intangibles fell 259.31% year-over-year to -$2.2 million; the trailing twelve-month figure through Dec 2023 stood at -$3.2 million (up 75.87% YoY), and the FY2023 full-year result was -$2.2 million, down 259.31% from the prior year.
• Change in Intangibles for Q4 2023 stood at -$2.2 million, down from -$598885.2 in the prior quarter.
• The five-year high for Change in Intangibles was -$39741.0 in Q2 2021, with the low at -$72.1 million in Q2 2019.
• Historically, Change in Intangibles has averaged -$21.1 million across 5 years, with a median of -$6.2 million in 2020.
• Annual changes were most pronounced in 2021 — Change in Intangibles surged 99.61% — and 2023, when it slumped 259.31%.
• Innate Pharma's Change in Intangibles stood at -$71.0 million in 2019, then jumped by 82.57% to -$12.4 million in 2020, then jumped by 96.29% to -$458732.4 in 2021, then tumbled by 30.55% to -$598885.2 in 2022, then tumbled by 259.31% to -$2.2 million in 2023.
• The last three Change in Intangibles figures came in at -$2.2 million (Q4 2023), -$598885.2 (Q4 2022), and -$458732.4 (Q4 2021), per Business Quant data.